The apatinib and pemetrexed combination has antitumor and antiangiogenic effects against NSCLC-Reference-Cited by-同舟云学术

The apatinib and pemetrexed combination has antitumor and antiangiogenic effects against NSCLC

Published:2023-01-01 Issue:1 Volume:18 Page:
ISSN:2391-5412
Container-title:Open Life Sciences
language:en
Short-container-title:

Author:

Zhou Ling¹,Zhang Wenchao²,Xiang Yi¹,Qian Zijun¹,Zhou Jianping¹,Ni Lei¹,Feng Yun¹,Gao Beili¹

Affiliation:

1. Department of Respiratory Medicine, Rui Jin Hospital, Shanghai Jiao Tong University, School of Medicine , Shanghai 200025 , China

2. Department of Allergy, Henan Provincial People’s Hospital, Henan University , Zhengzhou 450000 , China

Abstract

Abstract Chemotherapy for advanced non-small-cell lung cancer (NSCLC) remains the first treatment choice. Angiogenesis inhibitors are effective for lung cancer treatment. This study explored whether chemotherapy combined with angiogenesis inhibitors could achieve better efficacy in NSCLC. The zebrafish A549 xenograft model was used to investigate the combined effect of apatinib and chemotherapeutic agents in NSCLC. Apatinib combined with pemetrexed demonstrated the highest antitumor effect compared with apatinib combined with gemcitabine or paclitaxel in vitro. In the zebrafish A549 xenograft model, apatinib and pemetrexed, alone or in combination, showed significant inhibition of tumor growth. Co-treatment with apatinib and pemetrexed demonstrated the best antitumor effects, suggesting that the combination of apatinib and pemetrexed might be a promising alternative therapy for patients with lung cancer. Apatinib combined with pemetrexed had enhanced antitumor effects compared with either one alone in the zebrafish model of NSCLC.

Publisher

Walter de Gruyter GmbH

Subject

General Agricultural and Biological Sciences,General Immunology and Microbiology,General Biochemistry, Genetics and Molecular Biology,General Neuroscience

Link

https://www.degruyter.com/document/doi/10.1515/biol-2022-0533/pdf

Reference35 articles.

1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7–33.

2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.

3. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Non-Small Cell Lung Cancer. Version 3.2022. Fort Washington: National Comprehensive Cancer Network; 2022.

4. Novello S, Barlesi F, Califano R, Cufer T, Ekman S, Levra MG, et al. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27:v1–27.

5. Rivera MP, Mehta AC, Wahidi MM. Establishing the diagnosis of lung cancer: Diagnosis and management of lung cancer, 3rd edn. American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143:e142S–65S.